SOURCE: BioTech Medics Inc.

February 05, 2007 09:30 ET

BioTech Medics Targets SHBAN™ for European Countries

DALLAS, TX -- (MARKET WIRE) -- February 5, 2007 -- BioTech Medics, Inc. (PINKSHEETS: BTMD) announced today that they have commenced preliminary discussions with a major European Union (EU) distributor through an intermediary consultant in England to distribute BioTech's new product: "SHBAN™ 3 oz. Go Anywhere Hand Sanitizer Spray Bottle."

SHBAN has been clinically proven to kill the Avian Bird Flu and other viruses upon contact without harming humans, animals and the environment. Several EU countries have had outbreaks of the Avian Bird Flu among birds. The clear superiority of SHBAN over other disinfectants is that SHBAN is longer-lasting, it does not evaporate within one minute after application (compared to a popular alcohol-based hand sanitizer). SHBAN is non-toxic (when used as directed), it is non-bleaching and has no toxic odors. Additionally, the SHBAN 3oz. size is convenient to carry in a purse, briefcase, backpack, waist pouch or vehicle.

The Company developed SHBAN 3 oz. Go Anywhere so that it may pass the TSA carry-on guidelines for airline passengers and be used during travel.

The SHBAN™ solution, in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against S. Aureus, S. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Tests revealed that SHBAN was extremely effective against all species of bacteria that were tested. SHBAN has previously been tested by Baylor Medical Center in Houston, Louisiana State University, UT Houston, Allergan, Pathology Associates, MBA Labs and Texas A&M College of Veterinary Medicine. SHBAN is protected under US Letters of Patent #4,868,213, #5,514.808, #5,574,050, #5,679,711 5,679 and #5,585,391 and several EU and other foreign patents. BioTech Medics will provide SHBAN samples to government or world health officials should they desire to independently test the SHBAN solution.

BioTech Medics is a 21st Century Alternative Medicine company.

Safe Harbor for Forward-Looking Statements.

This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements.

Contact Information

  • Contact:
    BTMD Investor Relations